These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The cardiotoxicity of anticancer agents. Von Hoff DD; Rozencweig M; Piccart M Semin Oncol; 1982 Mar; 9(1):23-33. PubMed ID: 7071608 [TBL] [Abstract][Full Text] [Related]
4. Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer. Guldner L; Haddy N; Pein F; Diallo I; Shamsaldin A; Dahan M; Lebidois J; Merlet P; Villain E; Sidi D; Sakiroglu O; Hartmann O; Leftakopoulos D; de Vathaire F Radiother Oncol; 2006 Oct; 81(1):47-56. PubMed ID: 16989913 [TBL] [Abstract][Full Text] [Related]
5. [Cardiotoxicity as undesired side effect in the treatment of breast cancer]. Gramatyka M Postepy Hig Med Dosw (Online); 2014 May; 68():483-97. PubMed ID: 24864100 [TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Wiseman LR; Spencer CM Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314 [TBL] [Abstract][Full Text] [Related]
7. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Seymour L; Bramwell V; Moran LA Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762 [TBL] [Abstract][Full Text] [Related]
8. [Cardiac disease in patients with tumors and tumor therapy]. Hoppe UC Internist (Berl); 2007 Mar; 48(3):268-75. PubMed ID: 17287966 [TBL] [Abstract][Full Text] [Related]
9. [Treatment-related cardiotoxicity in childhood cancer survivors: Risk factors and follow-up]. Fresneau B; Fayech C; Butel T; Haddy N; Valteau-Couanet D; Ou P Rev Med Interne; 2017 Feb; 38(2):125-132. PubMed ID: 27639916 [TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy-induced cardiac toxicity and management]. Komagata H; Sakai H Gan To Kagaku Ryoho; 2003 Jun; 30(6):787-92. PubMed ID: 12852345 [TBL] [Abstract][Full Text] [Related]
11. Anticancer agents and cardiotoxicity. Ng R; Better N; Green MD Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642 [TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Pai VB; Nahata MC Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823 [TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of doxorubicin and other anthracycline derivatives. Jain D J Nucl Cardiol; 2000; 7(1):53-62. PubMed ID: 10698235 [No Abstract] [Full Text] [Related]
14. Managing anthracycline-induced cardiotoxicity: beginning with the end in mind. Salvatorelli E; Menna P; Minotti G Future Cardiol; 2015 Jul; 11(4):363-6. PubMed ID: 26239550 [No Abstract] [Full Text] [Related]
15. Cardiac manifestations of noncardiac tumors. Part II: Direct effects. Weinberg BA; Conces DJ; Waller BF Clin Cardiol; 1989 Jun; 12(6):347-54. PubMed ID: 2661069 [TBL] [Abstract][Full Text] [Related]